- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06417489
Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients
May 11, 2024 updated by: Peking University First Hospital
Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin Compared to Sequential Metformin Therapy in Newly Diagnosed Type 2 Diabetes Patients
This study evaluated the efficacy and safety of initial combined treatment of Henggliptin, Retagliptin and Metformin by including new type 2 diabetes patients.
This study is a multicenter, randomized, open label, positive control study.
It is planned to include 160 new type 2 diabetes patients who meet the inclusion criteria of the study.
The study is divided into three stages: screening period (V0, -14d-0), treatment period (V1-V8, D1-24w) and safe follow-up period (V9, 28w), with a total of 10 planned visits.
This study was divided into an experimental group and a control group.
The experimental group received a one-time addition of 10 mg qd of Henggliptin, 100 mg qd of Regagliptin, and 500mg of Metformin.
The control group was first treated with metformin.
If the blood sugar level did not meet the standard (fasting blood glucose (FPG)>7mmol/L, postprandial blood glucose (PPG)>10mmol/L), Henggeliflozin 10 mg qd was sequentially added.
If the blood sugar level did not meet the standard after 4 weeks, Regagliptin 100 mg qd was added.
During the follow-up period, evaluate blood glucose control, pancreatic islet function, and safety in both groups of patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Junqing Zhang
- Phone Number: 8613611167278
- Email: nan.gu@pkufh.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Untreated newly diagnosed T2DM patients;
- Age ≥ 18 years old;
- 8.0% ≤ HbA1c<11.0%;
- 19 kg/m2 ≤ BMI<35 kg/m2;
- eGFR ≥ 60 ml/min1.73m2;
- Voluntarily participate and sign an informed consent form
Exclusion Criteria:
- Pregnant and lactating women, as well as women of childbearing age who are unwilling to take reliable contraceptive measures;
- Individuals who are known to be allergic to Henggliflozin, Regagliptin, or Metformin;
- Other types of diabetes except type 2 diabetes;
- Type 2 diabetes with a history of ketoacidosis (DKA) in the last 6 months;
- NYHA cardiac grade IV patients;
- Within 30 days prior to the screening visit, admission due to acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery; Or plan to undergo percutaneous coronary intervention or cardiac surgery within 3 months.
- Confirmed respiratory system diseases (such as chronic obstructive pulmonary disease, pulmonary arterial hypertension, etc.);
- History of acute or chronic pancreatitis;
- Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg (average of three supine blood pressure measurements) during screening visits;
- Patients with orthostatic hypotension and/or systolic blood pressure<90 mmHg at visit 0 or visit 1, or clinically diagnosed as having low blood volume;
- Diagnosed malignant tumor patients with an expected life expectancy of less than 1 year;
- Patients with a history of recurrent urinary and reproductive tract infections (judged by clinical doctors);
- Patients who participate in other clinical trials within 3 months;
- Alcohol or drug addiction.
- In addition to the above, the researchers determined that patients who are not suitable to participate in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination therapy
Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid.
The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid.
If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient's tolerance situation.
The minimum dose is 1000mg/day.
|
Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid.
The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid.
If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient's tolerance situation.
The minimum dose is 1000mg/day.
|
Active Comparator: Sequential treatment group
Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid.
If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient's tolerance situation.
The minimum dose is 1000mg/day.
After the fourth week of treatment, blood glucose levels were measured.
For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)>7mmol/L, postprandial blood glucose (PPG)>10mmol/L), 10 mg qd of Henagliflozin Proline was sequentially added.
If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG>7mmol/L, PPG>10mmol/L), 100 mg qd of Ruigeliflozin was added
|
Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid.
If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient's tolerance situation.
The minimum dose is 1000mg/day.
After the fourth week of treatment, blood glucose levels were measured.
For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)>7mmol/L, postprandial blood glucose (PPG)>10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added.
If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG>7mmol/L, PPG>10mmol/L), 100 mg qd of Ruigeliflozin was added
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with HbA1c<7% at 12w
Time Frame: From enrollment to the end of treatment at 12 weeks
|
From enrollment to the end of treatment at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of subjects with HbA1c<7% at week 24
Time Frame: From enrollment to the end of treatment at 24 weeks
|
From enrollment to the end of treatment at 24 weeks
|
The proportion of subjects with HbA1c<6.5% at 12 week
Time Frame: From enrollment to the end of treatment at 12 weeks
|
From enrollment to the end of treatment at 12 weeks
|
The proportion of subjects with HbA1c<6.5% at 24 week
Time Frame: From enrollment to the end of treatment at 24 weeks
|
From enrollment to the end of treatment at 24 weeks
|
Changes in HbA1c compared to baseline at 12 weeks
Time Frame: From enrollment to the end of treatment at 12 weeks
|
From enrollment to the end of treatment at 12 weeks
|
Changes in HbA1c compared to baseline at 24 weeks
Time Frame: From enrollment to the end of treatment at 24 weeks
|
From enrollment to the end of treatment at 24 weeks
|
Changes in fingertip blood glucose (seven point blood glucose spectrum) compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in 2hPPG compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in FBG compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in systolic pressure compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in diastolic pressure compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in body weight compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in waist circumference compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in eGFR compared to baseline at 4w, 8w, 12w, and 24w
Time Frame: From enrollment to the end of treatment at 4/8/12/24 weeks
|
From enrollment to the end of treatment at 4/8/12/24 weeks
|
Changes in C-peptide levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods
Time Frame: From enrollment to the end of treatment at 12 and 24 weeks
|
From enrollment to the end of treatment at 12 and 24 weeks
|
Changes in insulin levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods
Time Frame: From enrollment to the end of treatment at 12 and 24 weeks
|
From enrollment to the end of treatment at 12 and 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 31, 2024
Primary Completion (Estimated)
May 30, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
May 11, 2024
First Submitted That Met QC Criteria
May 11, 2024
First Posted (Actual)
May 16, 2024
Study Record Updates
Last Update Posted (Actual)
May 16, 2024
Last Update Submitted That Met QC Criteria
May 11, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-165-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Combination therapy
-
Cairo UniversityCompletedNon Specific Knee Osteoarthritis PainEgypt
-
Riphah International UniversityRecruiting
-
University of PalermoCompleted
-
SpringWorks Therapeutics, Inc.Not yet recruiting
-
ID3 MedicalCompletedPeripheral Arterial DiseaseBelgium
-
Alcon ResearchCompletedOcular Hypertension | Glaucoma, Open-angleUnited States
-
National Taiwan University HospitalUnknown
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleSpain
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdPeking UniversityCompletedHER2-positive Solid TumorsChina
-
October 6 UniversityCompleted